

This group of articles, published in 2012 at various sources, evaluates status of commonly prescribed recommendations and treatments for Fibromyalgia, as follows:

[Omega-3 Trial Suggests 'a Nutritional Supplement Might Actually Make a Difference in Aging '](#) (ProHealth) An interesting article examining some of the benefits of supplemental omega-3 fatty acids as shown in a trial, "Omega-3 fatty acids, oxidative stress, and leukocyte telomere length: A randomized controlled trial," by Kiecolt-Glaser JK, et al. Ohio State University College of Medicine and College of Public Health; University of California, San Francisco, CA, published in *Brain, Behavior, and Immunity*, Sept. 23, 2012.

[Fibro Doctors Chose Pfizer Over You](#) (Fibromyalgia Network, posted May 30, 2012) An editorial by Kristin Thorson, founder and editor of the Fibromyalgia Network, on the FibroCollaborative Roadmap for Change program. Disclaimer: This editorial is being provided as a source of information. The opinions expressed are those of the author and do not necessarily state or reflect the views of Massachusetts CFIDS/ME & FM Association.

[FibroCollaborative Roadmap for Change: A Call to Action for Fibromyalgia](#) A link to this publication (as a twenty page PDF) is available at the Nurse Practitioners in Women's Health (NPWH) organization. However, this program, the FibroCollaborative, was developed by an advocacy working group co-chaired by Drs. Daniel Clauw and Bill McCarberg and sponsored by Pfizer, Inc. Key objectives of this program are to improve awareness and understanding of FM, improve recognition and diagnosis of FM as well as promote better communication between healthcare providers and patients. This program/initiative also includes recommendations for effective management of FM.

[Increase in Diagnosis Rates and Penetration into New Markets Drives the Global Fibromyalgia Therapeutics Market, According to New Report by Global Industry Analysts, Inc.](#) (PR Web) An article that takes a look at unmet medical needs for Fibromyalgia from a business standpoint.

["Milnacipran Beneficial for Fibromyalgia in Patients With Inadequate Response to Duloxetine"](#) (Monthly Prescribing Reference (MPR) Review of two FM-specific medications (i.e., milnacipran (brand name, Savella) and duloxetine (brand name, Cymbalta) that includes study observations/ recommendations made by Dr. Lucinda Bateman at The Fatigue Consultation Clinic in Salt Lake City, UT.

[Fibro Out-of-Control?](#) (One of the free, sample articles available at Fibromyalgia Network) Dr. Charles Lapp and Dr. Carol Beals explain why FM symptoms get worse and offer ways to tackle.

[Clinical Context series - Fibromyalgia](#) (MedPage Today) All articles discussing various aspects of FM, published by MedPage Today, are listed at this webpage.

["Low-Dose Naltrexone for Autoimmune Diseases and Fibromyalgia? The Unfinished Story"](#)
(ProHealth, Dec. 21, 2011)